Annovis Bio Surpasses 850 Patient Enrollment Milestone in Alzheimer's Trial
ANVS•Annovis Bio has enrolled more than 850 patients in its upcoming Alzheimer’s disease trial, marking rapid recruitment progress ahead of planned dosing. The expanded cohort de-risks the study timeline and enhances potential for a robust efficacy assessment across cognitive and biomarker endpoints.
1. Enrollment Progress
Annovis Bio has completed enrollment of over 850 patients in its next Alzheimer’s disease trial, achieving its recruitment goal ahead of schedule. This accelerated process across multiple clinical sites underscores strong operational execution and patient interest, positioning the study to move swiftly into the dosing phase.
2. Trial Design and Timelines
The multicenter study will evaluate safety, tolerability and cognitive outcomes over a 12-month treatment course, with interim biomarker analyses planned to track disease modification. With full enrollment reached, Annovis Bio can now focus on dosing logistics and anticipates initial outcome assessments in the latter half of next year.
3. Impact on Company Outlook
Completing this enrollment milestone reduces a key development risk and strengthens Annovis Bio's negotiating position for potential partnerships or licensing agreements. Progress toward clinical milestones may boost investor confidence and support the company’s valuation ahead of upcoming data readouts.
